ArticleNature communications2024
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 23 citations in OpenAlex.
- UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition.Cell death and differentiation · 2026Article
- Article
- Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.International journal of molecular sciences · 2026Review
- Review
- Phenotypic Characterization and Prognostic Impact of CD103+ Tissue-Resident Memory T Cells in Diffuse Large B-cell Lymphoma.Cancer immunology research · 2026Article
- Artificial Intelligence-Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance.Journal of multidisciplinary healthcare · 2026Review
- Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities.Frontiers in oncology · 2026Review
- Mouse models of B cell lymphomas on the basis of genetic features.Frontiers in immunology · 2026Review
- T follicular helper cells transiently unlock a plasticity state in germinal centre B cells during the humoral immune response.Nature cell biology · 2026Article
- Association of Secondary Primary Malignancies in Cutaneous Lymphoma: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement.Genome medicine · 2025Article
- Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy.Biomedicines · 2025Article
- Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.Blood · 2025Review
- Article
- Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease.Signal transduction and targeted therapy · 2025Review
- Whole genome sequencing and single-cell transcriptomics identify KMT2D inactivation as a potential new driver for pituitary tumors: a case report.BJC reports · 2025Article
- Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma.PLoS biology · 2025Article
- High Tumor Mutation Burden (TMB) and a Novel Somatic Mutation in the TREX1 Gene in a Patient with Aggressive and Refractory High-Grade B-Cell Lymphoma: A Case Report.International journal of molecular sciences · 2025Article
- Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.Cell death discovery · 2025Review
Corrections and comments
- Update of
Authors and funding
24 authors at 7 institutions in 3 countries.
Jie Li *Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.ORCID http://orcid.org/0000-0003-4816-957X
Christopher R Chin *Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.ORCID http://orcid.org/0000-0002-2140-3197
Hsia-Yuan Ying *Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Cem MeydanDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-0663-6216
Matthew R TeaterDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Min XiaDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Pedro FarinhaBC Cancer Centre for Lymphoid Cancer, Department of Pathology and Laboratorial Medicine, University of British Columbia, Vancouver, Canada.ORCID http://orcid.org/0000-0001-9364-9391
Katsuyoshi TakataCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada.
Chi-Shuen ChuThe Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, USA.
Yiyue JiangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-5488-9763
Jenna EaglesPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Verena PasseriniDepartment of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Ludwig-Maximilians University (LMU) Hospital, Munich, Germany.
Zhanyun TangThe Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, USA.
Martin A RivasDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.ORCID http://orcid.org/0000-0002-9603-6897
Oliver WeigertDepartment of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Ludwig-Maximilians University (LMU) Hospital, Munich, Germany.ORCID http://orcid.org/0000-0002-0987-7373
Trevor J PughPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-8073-5888
Amy ChadburnDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Christian SteidlCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada.ORCID http://orcid.org/0000-0001-9842-9750
David W ScottBC Cancer Centre for Lymphoid Cancer, Department of Medicine, University of British Columbia, Vancouver, Canada.ORCID http://orcid.org/0000-0002-0435-5947
Robert G RoederThe Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-3865-8572
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1850-1642
Roberta ZappasodiDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.ORCID http://orcid.org/0000-0002-7031-6671
Wendy BéguelinDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA. web2002@med.cornell.edu.ORCID http://orcid.org/0000-0002-4894-9229
Ari M MelnickDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA. amm2014@med.cornell.edu.ORCID http://orcid.org/0000-0002-8074-2287
Cornell University · USRockefeller University · USLudwig-Maximilians-Universität München · DESpinal Cord Injury BC · CAUniversity Health Network · CAUniversity of British Columbia · CAOntario Institute for Cancer Research · CA
Funding
Project 4 Green-DavisP01CA272295 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Sanjay Shutish Patel · 2024 to 2026
$9.3MProject 3: Targeting PRMT5 in Mantle Cell LymphomaP01CA214274 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI INGHIRAMI, GIORGIO · 2018 to 2022
$8.9MTargeting Epigenetic Circuits in B-Cell LymphomasR35CA220499 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2018 to 2024
$7.2MFunctions and mechanisms of transcriptional coactivator OCA-B in B cell development and lymphomagenesisR01AI148387 · NIAID · ROCKEFELLER UNIVERSITY · PI ROEDER, ROBERT G · 2020 to 2024
$3.7MClinical and Molecular Heterogeneity in the Myelodysplastic SyndromesR01CA249054 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MASON, CHRISTOPHER EDWARD, PARK, CHRISTOPHER Y · 2020 to 2024
$3.5MThe Spatiotemporal Landscape of the Human Brain EpitranscriptomeR01MH117406 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI MASON, CHRISTOPHER EDWARD · 2018 to 2022
$3.3MTargeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to ImmunotherapyR01CA282889 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Roberta Zappasodi · 2023 to 2026
$2.4MPreventing follicular lymphoma progression and transformation through precision therapyR01CA270245 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Wendy Beguelin · 2022 to 2026
$2.2MDisruption of epigenetic regulation of enhancers in the germinal center reaction drives clonal evolution in Follicular LymphomaF31CA254302 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIN, CHRISTOPHER RUSSELL · 2020 to 2022
$138kNCI NIH HHS F31 CA254302NCI NIH HHS P01 CA214274NCI NIH HHS P01 CA272295NCI NIH HHS R01 CA249054NCI NIH HHS R01 CA270245NCI NIH HHS R01 CA282889NCI NIH HHS R35 CA220499NIAID NIH HHS R01 AI148387NIMH NIH HHS R01 MH117406
Abstract
Despite regulating overlapping gene enhancers and pathways, CREBBP and KMT2D mutations recurrently co-occur in germinal center (GC) B cell-derived lymphomas, suggesting potential oncogenic cooperation. Herein, we report that combined haploinsufficiency of Crebbp and Kmt2d induces a more severe mouse lymphoma phenotype (vs either allele alone) and unexpectedly confers an immune evasive microenvironment manifesting as CD8
Indexed as
Lymphoma, Large B-Cell, DiffuseAnimalsB-LymphocytesChromatinCREB-Binding ProteinGerminal CenterHistone-Lysine N-MethyltransferaseMiceMutationMyeloid-Lymphoid Leukemia ProteinTumor MicroenvironmentChromatinCREB-Binding ProteinCrebbp protein, mouseHistone-Lysine N-MethyltransferaseKmt2d protein, mouseMyeloid-Lymphoid Leukemia Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.